To extend the function of NK3R agonists serving as a valid inhibitor of angiogenesis with the selectivity targeting property to the tumor related angiogenesis site, two endothelial cells targeting sequence, NGR and CNGRC, were used to construct novel anti-angiogenic peptide analogues. Here, TACR3 is linked to neoplasm.